Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

Peer Review reports

Original Submission
28 Nov 2019	Submitted	Original manuscript
28 Jan 2020	Reviewed	Reviewer Report - Sae Ochi
2 Feb 2020	Reviewed	Reviewer Report - Kazuhisa Nakano
2 Mar 2020	Author responded	Author comments - Shubhadeep Sinha
15 Mar 2020	Reviewed	Reviewer Report - Sae Ochi
17 Mar 2020	Author responded	Author comments - Shubhadeep Sinha
Resubmission - Version 2
2 Mar 2020	Submitted	Manuscript version 2
Publishing
18 Mar 2020	Editorially accepted
4 Jun 2020	Article published	10.1186/s41927-020-00124-9

Back to article page